title: Rapidly Progressive Seeding of a Community Acquired Pathogen in an Immune-competent Host--End Organ Damage from Head to Bone.
abstract: This report describes a 64-years-old male patient that presented to our hospital with a chief complaint of acute worsening of his usual chronic lower back pain, progressive weakness in lower extremities and subjective fevers at home. Spine CT failed to demonstrate any infectious foci but showed partially visualized lung cavitary lesion and renal pole abnormalities. Blood cultures grew methicillin-sensitive Staphylococcus Aureus (MSSA). Transthoracic echocardiogram (TTE) showed no signs of infective endocarditis (IE). Later, the patient experienced an acute deterioration on clinical status and examination showed development of a new murmur. He also developed new hemiparesis with up-going babinski reflex. A head MRI showed multiple infarcts. MRI spine displayed osteomyelitis at T12-L1. Cerebro-spinal fluid was positive for meningitis. A transesophageal echocardiogram (TEE) was performed demonstrating new severe mitral and mild tricuspid regurgitations with a definitive 1.5 cm mobile vegetation on posterior mitral leaflet. We present is a very interesting case of a rapidly progressive MSSA infection. MSSA meningitis is a rare disease; there are only few reported cases in the literature to date. We describe a case of MSSA bacteremia, of questionable source, that resulted in MSSA endocarditis affecting right and left heart in a patient who did not have a history of intravenous drug use (IVDU) or immunosuppression. The case was complicated by septic emboli to systemic circulation involving the kidneys, vertebral spine (osteomyelitis), lungs and brain with consequent meningitis and stroke. Even when MSSA infections are well known, to our knowledge there are no previous case reports describing such an acute-simultaneous-manifestation of multi-end-organ failure, including meningitis and stroke. These latter are rarely reported, even individually.
authors.forename: Daisy
authors.initials: D
authors.lastname: Torres-Miranda
authors.forename: Farah
authors.initials: F
authors.lastname: Al-Saffar
authors.forename: Saif
authors.initials: S
authors.lastname: Ibrahim
authors.forename: Stephanie
authors.initials: S
authors.lastname: Font-Diaz
mesh_terms: D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D003131:Combined Modality Therapy; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D018450:Disease Progression; D004352:Drug Resistance, Microbial; D057915:Drug Substitution; D017548:Echocardiography, Transesophageal; D004697:Endocarditis, Bacterial / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology / Q000601:surgery; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D007121:Immunocompetence; D008297:Male; D016920:Meningitis, Bacterial / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D008875:Middle Aged; D009254:Nafcillin / Q000627:therapeutic use; D010019:Osteomyelitis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D010291:Paresis / Q000209:etiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D020521:Stroke / Q000209:etiology; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D009254:Nafcillin; D014640:Vancomycin